Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer

Overview of attention for article published in BMC Urology, May 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#41 of 758)
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 2 news outlets

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 18 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

Medical Health News, 26 Jun 2019

Arnulf Stenzl, MD Enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sen…

Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

OncLive, 25 Jun 2019

Arnulf Stenzl, MD Enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sen…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.